HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc. (HOOK) priced its initial public offering on Apr 19, 2019 at $14.00 per share, within its $14.00–$16.00 range, raising $84M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $302.2M. Leerink Partners was lead-left underwriter, joined by RBC Capital Markets. Goodwin Procter advised the company and A&O Shearman advised the underwriters.

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for infectious diseases and cancers using its proprietary arenavirus platform. Its lead infectious disease candidate, HB-101, is in a Phase 2 trial in cytomegalovirus-negative patients awaiting a kidney transplant from cytomegalovirus-positive donors.

Status

IPO

Ticker

HOOK

Exchange

Nasdaq Global Select

Priced

Apr 19, 2019

IPO price

$14.00

Price range

$14.00–$16.00

Raised

$84M

Market cap at IPO price

$302.2M

First filed

Mar 22, 2019

Underwriters

Leerink Partners and RBC Capital Markets

Company counsel

Goodwin Procter

Underwriters' counsel

A&O Shearman

Sector

Biotech & pharma

Country / state

NY

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.